Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.65 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.65 |
| ▸ | OSBP | P22059 | 1/20 | 0.65 |
| ▸ | RORC | P51449 | 1/20 | 0.65 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.65 |
| ▸ | POLA1 | P09884 | 1/20 | 0.61 |
| ▸ | GRIN1 | Q05586 | 11/20 | 0.60 |
| ▸ | GRIN2B | Q13224 | 11/20 | 0.60 |
| ▸ | GRIN2A | Q12879 | 9/20 | 0.60 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6060845 | 0.90 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL27963051 | 0.90 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL27963054 | 0.90 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL2638134 | 0.90 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL27975861 | 0.90 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL18631920 | 0.90 | USP2 (0.63) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL8426935 | 0.90 | USP2 (0.67) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL2221515 | 0.90 | USP2 (0.67) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL2637585 | 0.90 | USP2 (0.67) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL8159169 | 0.88 | OSBP (0.65) | USP2CYP46A1LMNAABCB1OSBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872261-B2 | Lipoprotein targeting protease inhibitors and uses | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230201298-A1 | LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2023-06-29 | — | — | US | disclosed |
| US-20220168379-A1 | LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2022-06-02 | — | — | US | disclosed |
| EP-3721943-A1 | LIPIDS, LIPID COMPOSITIONS AND METHODS OF USING THEM | Novartis AG (CH) | 2020-10-14 | — | — | EP | disclosed |
| US-20200078434-A1 | LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2020-03-12 | — | — | US | disclosed |
| EP-2205283-B1 | CHOLESTEROL CONJUGATES OF INHIBITORS OF VIRAL FUSION | MSD ITALIA SRL (IT) | 2019-03-20 | — | — | EP | disclosed |
| US-20170319643-A1 | LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2017-11-09 | — | — | US | disclosed |
| US-9301923-B2 | Lipids, lipid compositions, and methods of using them | NOVARTIS AG (CH) | 2016-04-05 | — | — | US | disclosed |
| US-20140309277-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | NOVARTIS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-8629101-B2 | Cholesterol derivatives of inhibitors of viral fusion | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) | 2014-01-14 | — | — | US | disclosed |
| US-20110200582-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| WO-2011076807-A2 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | NOVARTIS AG (CH) | 2011-06-30 | — | — | WO | disclosed |
| US-20100305028-A1 | CHOLESTEROL DERIVATIVES OF INHIBITORS OF VIRAL FUSION | MSD ITALIA S.R.L. (IT) | 2010-12-02 | — | — | US | disclosed |
| US-7803378-B2 | Antigen imitating extracellular areas of membrane proteins of type III produced from intracellular pathogenic micro-organisms, derived conformational antibodies and the use thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE | 2010-09-28 | — | — | US | disclosed |
| WO-2010089129-A1 | INHIBITORS OF VIRAL FUSION AND USES THEREOF | CORMUS SRL (IT) | 2010-08-12 | — | — | WO | disclosed |
| EP-2205283-A2 | CHOLESTEROL DERIVATIVES OF INHIBITORS OF VIRAL FUSION | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009053339-A2 | CHOLESTEROL DERIVATIVES OF INHIBITORS OF VIRAL FUSION | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2009-04-30 | — | — | WO | disclosed |
| US-20080075717-A1 | Antigen Imitating Extracellular Areas of Membrane Proteins of Type III Produced from Intracellular Pathogenic Micro-Organisms, Derived Conformational Antibodies and the Use Thereof | UNIVERSITE DE LILLE 2 (FR) | 2008-03-27 | — | — | US | disclosed |
| EP-1587825-A2 | ANTIGEN IMITATING EXTRACELLULAR AREAS OF MEMBRANE PROTEINS OF TYPE III PRODUCED FROM INTRACELLULAR PATHOGENIC MICRO-ORGANISMS, DERIVED CONFORMATIONAL ANTIBODIES AND THE USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2005-10-26 | — | — | EP | disclosed |
| WO-2004069140-A2 | ANTIGEN IMITATING EXTRACELLULAR AREAS OF MEMBRANE PROTEINS OF TYPE III PRODUCED FROM INTRACELLULAR PATHOGENIC MICRO-ORGANISMS, DERIVED CONFORMATIONAL ANTIBODIES AND THE USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305028-A1 | CHOLESTEROL DERIVATIVES OF INHIBITORS OF VIRAL FUSION | HDLBP, CETP, NPC1 | USP2 1567/4885CYP46A1 10/4885LMNA 2492/4885 |
| US-20110200582-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | SGMS1, SGMS2, LIPC | USP2 4382/4885CYP46A1 92/4885LMNA 401/4885 |
| US-11872261-B2 | Lipoprotein targeting protease inhibitors and uses | SERPINB1, APOB, APOL1 | USP2 791/4885CYP46A1 291/4885LMNA 410/4885 |
| US-20200078434-A1 | LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES | SERPINB1, APOB, APOL1 | USP2 791/4885CYP46A1 291/4885LMNA 410/4885 |
| US-20140309277-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | SGMS1, SGMS2, LIPC | USP2 4382/4885CYP46A1 92/4885LMNA 401/4885 |
| US-20170319643-A1 | LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES | SERPINB1, APOB, APOL1 | USP2 791/4885CYP46A1 291/4885LMNA 410/4885 |
| US-20230201298-A1 | LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES | HPN, SERPINB1, PEPD | USP2 636/4885CYP46A1 342/4885LMNA 798/4885 |
| US-20220168379-A1 | LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES | SERPINB1, APOB, APOL1 | USP2 791/4885CYP46A1 291/4885LMNA 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.